News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Arndt Vogel/X
Apr 1, 2025, 11:25

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Daniel H. Palmer, et al. on X:

“Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Supports GemCap for R0 & lymph node-negative patients not eligible for mFOLFIRINOX.”

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Authors: Daniel H. Palmer, et al.

Arndt Vogel: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial

Adjuvant Therapy Arndt Vogel cancer Daniel H. Palmer 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 ESPAC4 fight against cancer Gastroenterology Global fight against cancer Hannover Medical School Hepatology mFOLFIRINOX OncoDaily Oncology pancreatic adenocarcinoma
Special Coverage
Blog
May 16, 2025, 13:01
How Countries are Engaging Stakeholders in the Development and Implementation of NCCPs - Union for International Cancer Control
Oncolibrary
May 16, 2025, 12:59
Eating Well with Mesothelioma: What You Need to Know
Blog
May 16, 2025, 12:54
Douglas Flora: Fantastic day Connecting with the Incredible Leaders at St. Elizabeth Healthcare
Blog
May 16, 2025, 12:37
Impact of Research Through Maggie’s Lung Cancer Journey - LUNGevity Foundation
Blog
May 16, 2025, 12:28
Giulio Draetta: A $150 million Gift from Kinder Foundation
Blog
May 16, 2025, 12:19
Environmental Risk Factors of Wilms Tumour - Childhood Cancer and Leukemia International Consortium
Science
May 16, 2025, 12:17
ROSALINE Trial Reports 49% Response in Lobular Breast Cancer at ESMO 2025
Oncolibrary
May 16, 2025, 11:45
DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer
Blog
May 16, 2025, 11:26
Antonio Giordano: Important question - which 1L CDK4/6i to preserve efficacy of re-cycling cell cycle in 2L?
Oncolibrary
May 16, 2025, 11:22
FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial
Blog
May 16, 2025, 10:40
€1 Million Innovation Grant Awarded to Joshua Waterfall for Pediatric Cancer Research - KickCancer
Blog
May 16, 2025, 10:25
Whole-Patient Care Cannot be an Afterthought - European Cancer Organisation